Related Experiment Video
Updated: Sep 28, 2025
09:28
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 25, 2010
13.3K
Valproate-Induced Bicytopenia: A Case Study.
Varun Jaitpal1, Sushil Gawande1
1Psychiatry, NKP (Narendra Kumar Prasadrao) Salve Institute of Medical Sciences and Lata Mangeshkar Hospital, Nagpur, IND.
Cureus
|April 4, 2022
Summary
A patient with schizoaffective disorder developed bicytopenia (low platelets and white blood cells) due to sodium valproate. Switching to lithium resolved the issue, emphasizing the need for blood monitoring during treatment.
Area of Science:
- Psychiatry
- Pharmacology
- Hematology
Background:
- Schizoaffective disorder is a serious mental health condition requiring complex pharmacotherapy.
- Adverse drug reactions, particularly hematological complications, can significantly impact patient safety and treatment outcomes.
Observation:
- A 22-year-old male patient with schizoaffective disorder was treated with olanzapine and lorazepam.
- Sodium valproate was added, leading to the development of thrombocytopenia and leukopenia (bicytopenia).
Findings:
- Sodium valproate was identified as the causative agent for the bicytopenia.
- Discontinuation of sodium valproate and substitution with lithium resulted in complete patient recovery without further adverse events.
Implications:
- This case underscores the critical importance of vigilant monitoring of blood indices in patients receiving sodium valproate.
- Regular laboratory investigations are essential for early detection and management of potentially fatal adverse drug reactions in psychiatric pharmacotherapy.
- Lithium may serve as a viable alternative in cases where sodium valproate-induced bicytopenia occurs.
More Related Videos
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
325
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
325
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Vitamins
1.0K
Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced...
1.0K
01:28Drug Biotransformation: Overview
1.6K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
1.6K
01:09Hepatic Drug Clearance: Effect of Protein Binding
323
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
323
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
306
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
306